Section 4.3: Clinical Pharmacogenomics & Personalized Therapeutics

Clinical Pharmacogenomics & Personalized Therapeutics

Principles of Clinical Pharmacogenomics

Pharmacogenomics (PGx) studies how genetic variations affect an individual's response to drugs, aiming to optimize efficacy and minimize adverse drug reactions (ADRs). Key clinical recommendations are developed by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and are integrated into drug labeling worldwide, including by the Saudi Food and Drug Authority (SFDA). Clinicians must understand the translation of genetic genotypes (e.g., wild-type, variant alleles) into clinical phenotypes (e.g., poor, intermediate, normal, ultra-rapid metabolizers) to adjust dosing or select alternative agents.

---

Mandatory and Key Clinical Gene-Drug Pairs

1. HLA-B*5701 and Abacavir

Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) used in HIV treatment.

• Clinical Significance: Carriage of the HLA-B*5701 allele is strongly associated with abacavir hypersensitivity reaction (HSR), a multi-system, life-threatening immunological reaction characterized by fever, rash, gastrointestinal symptoms, and respiratory distress.
• Clinical Action: Genetic screening for HLA-B5701 is mandatory prior to initiating abacavir. If the patient is HLA-B5701 positive, abacavir is contraindicated and must be avoided. If negative, abacavir can be initiated but the patient should still be monitored, as a negative test reduces but does not completely eliminate the risk of HSR.

2. CYP2C19 and Clopidogrel

Clopidogrel is an antiplatelet prodrug used to prevent ischemic events in patients undergoing percutaneous coronary intervention (PCI) or presenting with acute coronary syndrome (ACS).

• Mechanism: Clopidogrel requires two-step hepatic bioactivation, primarily mediated by the CYP2C19 enzyme, to form its active thiol metabolite which irreversibly binds to platelet $\text{P2Y}_{12}$ receptors.
• Phenotypic Classifications & Actions:
  • *Poor Metabolizers (PMs - e.g., $*2/*2$, $*2/*3$, $*3/3$) and *Intermediate Metabolizers (IMs - e.g., $*1/*2$, $*1/3$): These patients have significantly reduced active metabolite levels, leading to high on-treatment platelet reactivity and an increased risk of major adverse cardiovascular events, particularly stent thrombosis. Clinical Action: Avoid clopidogrel. Use alternative antiplatelet therapies, such as prasugrel or ticagrelor, which do not rely on CYP2C19 for activation (unless contraindicated due to high bleeding risk or history of stroke/TIA for prasugrel).
  • *Ultra-rapid Metabolizers (UMs - $*17/17$): These patients have increased enzyme activity, leading to higher active metabolite levels and potentially a higher risk of bleeding. Clinical Action: Standard clopidogrel dosing is recommended, but clinicians should monitor for bleeding signs.

3. CYP2C9/VKORC1 and Warfarin

Warfarin is an oral anticoagulant with a narrow therapeutic index.

• Pharmacodynamics (VKORC1): Warfarin exerts its effect by inhibiting Vitamin K Epoxide Reductase Complex subunit 1 (VKORC1), preventing the recycling of vitamin K. The promoter polymorphism $-1639\text{G}>\text{A}$ is associated with reduced VKORC1 expression. Patients with the $ ext{A}/\text{A}$ genotype have less VKORC1 enzyme and are highly sensitive to warfarin, requiring lower starting doses.
• Pharmacokinetics (CYP2C9): S-warfarin (the active enantiomer) is metabolized primarily by CYP2C9. The wild-type allele is $ ext{CYP2C9}^*1$. The variant alleles $ ext{CYP2C9}^*2$ and $ ext{CYP2C9}^*3$ exhibit reduced enzymatic activity. Carriers of $*2$ or $*3$ alleles clear warfarin slowly, have prolonged half-lives, and are at high risk of over-anticoagulation and major hemorrhage. They require significantly lower starting doses and take longer to reach a stable International Normalized Ratio (INR).

4. SLCO1B1 and Simvastatin

The SLCO1B1 gene encodes the Organic Anion Transporting Polypeptide 1B1 (OATP1B1) influx transporter, which facilitates the uptake of statins from the blood into hepatocytes.

• Clinical Significance: The $ ext{SLCO1B1}^*5$ variant allele ($ ext{c.521T}>\text{C}$) results in reduced transporter activity, leading to decreased hepatic uptake and elevated systemic concentrations of simvastatin.
• Clinical Action: Guided by elevated systemic exposure of simvastatin is strongly linked to skeletal muscle toxicity (myalgia, myopathy, and rhabdomyolysis). Carriers of the C allele ($ ext{T}/\text{C}$ or $ ext{C}/\text{C}$) should avoid high-dose simvastatin (40 mg or 80 mg). If a statin is indicated, use a lower dose of simvastatin, or preferably switch to a different statin with lower dependency on OATP1B1, such as rosuvastatin or atorvastatin.

5. CYP2D6 and Codeine

Codeine is an opioid analgesic prodrug that must be metabolized by CYP2D6 into its active form, morphine, to provide pain relief.

• Clinical Phenotypes:
  • Ultra-rapid Metabolizers (UMs): Carry multiple copies of active CYP2D6 genes. They rapidly convert codeine to morphine, leading to toxic levels of morphine. This can cause life-threatening respiratory depression. Codeine is contraindicated in UMs (and has black box warnings against use in pediatric tonsillectomy/adenoidectomy and nursing mothers who are UMs, as morphine can pass through breast milk).
  • Poor Metabolizers (PMs): Lack functional CYP2D6 enzymes. They cannot convert codeine to morphine and experience no analgesic benefit. Avoid codeine; use alternative non-codeine analgesics (e.g., NSAIDs, acetaminophen, or non-CYP2D6 metabolized opioids).

6. Other Key PGx Pairs in Clinical Practice

• TPMT / NUDT15 and Thiopurines (Azathioprine, Mercaptopurine): Thiopurine S-methyltransferase (TPMT) and Nudix hydrolase 15 (NUDT15) are involved in thiopurine metabolism. Patients with genetic deficiencies in either enzyme accumulate toxic thiopurine metabolites in the bone marrow, resulting in life-threatening myelosuppression. Perform pre-treatment testing. Reduce doses by 30-90% for intermediate metabolizers, and use alternative agents or reduce dose by 10-fold (with extreme caution) in poor metabolizers.
• CYP2C9/HLA-B*1502 and Phenytoin: Carrying the HLA-B*1502 allele (most common in Asian populations) puts patients at risk for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when initiated on phenytoin or carbamazepine. Additionally, CYP2C9 poor metabolizers clear phenytoin slowly and require dose reductions.